CYX Cytomyx Hldgs

RNS Number:6037K
Cytomyx Holdings PLC
05 April 2005


For immediate release                                              5 April 2005



                              CYTOMYX HOLDINGS PLC
                          ("Cytomyx" or "the Company")


                   Cytomyx Announces Appointment to the Board
                              of Dr. Michael Evans


Cytomyx Holdings plc (AIM: CYX), a leading provider of drug discovery products
and services, is pleased to announce that Dr. Michael Evans is to join the Board
of Cytomyx as an independent Non-Executive Director.


Dr. Evans, 47, is an Executive Director of Oxford Gene Technology Limited and
Oxford Gene Technology IP Limited and will become Chief Executive of the Oxford
Gene Technology group in June 2005. He was previously Executive Vice President,
Marketing and Strategy, Discovery Systems business at  Amersham Biosciences, now
part of GE Healthcare. Prior to this, he was General Manager of Ascot Fine
Chemicals, a business unit of Ascot plc which was subsequently bought by Dow
Chemical Company, from 2000-2001. He was also a director of Chirotech Technology
Limited from 2000-2001. Between 1987 and 2000, Dr. Evans held a variety of
leading roles in business development at Amersham, culminating in the role of
Vice President for Corporate Development with responsibility for their drug
discovery business. Dr. Evans holds a BA and D.Phil in Biochemistry from the
University of Oxford.


Cytomyx also announces that Dr. Nick Pay will step down as a Non-Executive
Director, after three years with the company. The Cytomyx Board thanks him for
his input and support.


Dr. Bill Mason, Cytomyx' Chairman, said: "We are delighted that Dr. Evans is
joining the Cytomyx Board of Directors. His extensive experience in commercial
development at Amersham Biosciences, now part of GE Healthcare, will provide a
substantial and relevant resource for Cytomyx as we move forward with
development of our products and services for the global pharmaceutical
community. There are considerable synergies in our approach to drug discovery
companies and these will benefit the exciting growth that Cytomyx expects over
coming years."


Commenting on joining Cytomyx' Board, Dr. Michael Evans said: "I am delighted to
be joining the Cytomyx Board and look forward to assisting Cytomyx in its
development as a leader in providing innovative products and services to the
pharmaceutical and academic research markets."



                                        ENDS



For further information, please contact:

Cytomyx Holdings plc
Mike Kerins, Chief Executive                                + 44 (0) 1223 508191

Buchanan Communications                                    + 44 (0) 20 7466 5000
Mark Court/Mary-Jane Johnson

The Wall Street Group, Inc.                                      +1 212 888 4848
Ron Stabiner





Notes for editors

About Cytomyx Holdings plc

Cytomyx Holdings plc is a rapidly growing life science company based in
Cambridge, UK. The Company's primary focus is on developing novel technologies
that assist pharmaceutical and biotechnology companies in their efforts to
develop new treatments more effectively. This it does by providing solutions
that provide early insights into the likely efficacy and safety profile of new
drugs in development. The Company has two main areas of expertise: the use of
human clinical samples in understanding the linkage between gene expression and
disease and the development of cell-based assays that are used to predict
potential toxicity in new drugs.  Cytomyx is listed on the AIM market of the
London Stock Exchange (CYX.L). For more information visit
www.cytomyx-holdings.com







                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

BOAILFEDSSISIIE

Cytomyx (LSE:CYX)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024

Cytomyx (LSE:CYX)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024